---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-23-006541"
form_type: "8-K"
ticker: "LFST"
cik: "0001845257"
company_name: "LifeStance Health Group, Inc."
filed_at: "2023-03-08T23:59:59+00:00"
generated_at: "2026-06-18T08:49:08.759733+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# LifeStance Q4 revenue $229.4M (+21% YoY); net loss $46.7M; 2023 rev guidance $980M-$1.02B

## Summary
- Q4 revenue $229.4M (+21% YoY), full year revenue $859.5M (+29% YoY).
- Q4 net loss $46.7M, full year net loss $215.6M; adjusted EBITDA Q4 $10.2M (4.4% margin), full year $52.7M (6.1% margin).
- Clinician base grew 18% to 5,631; added 200 net clinicians in Q4.
- 2023 guidance: revenue $980M-$1.02B, Center Margin $270-290M, Adjusted EBITDA $50-62M.

## SEC filing metadata
- accession: 0000950170-23-006541
- form_type: 8-K
- ticker: LFST
- cik: 0001845257
- company_name: LifeStance Health Group, Inc.
- filed_at: 2023-03-08T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 5.03, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1845257/000095017023006541/0000950170-23-006541-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1845257/000095017023006541/lfst-20230308.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-23-006541
- JSON: https://secwatch.observer/filing/0000950170-23-006541.json
- Plain text: https://secwatch.observer/filing/0000950170-23-006541.txt

## Key facts
- Earnings Releases
  LifeStance Health Group, Inc. reported the fourth quarter and full year ended December 31, 2022 results: revenue $229.4 million, net income $46.7 million. Guidance initiated.
  - Period: the fourth quarter and full year ended December 31, 2022
  - Revenue: $229.4 million
  - Net income: $46.7 million
  - Guidance: initiated
  - Result: reported results
  source text: December 31, 2022. (All results compared to prior-year comparative period, unless otherwise noted) 2022 Highlights and 2023 Outlook • Fourth quarter revenue increased 21% to $229.4 million and full year revenue of $859.5 million increased $192.0 million or 29% compared to revenue of $667.5 million • Clinician base increased 18% to 5,631 clinicians, including 200
  evidence_url: https://www.sec.gov/Archives/edgar/data/1845257/000095017023006541/0000950170-23-006541-index.htm
- Governance Changes
  LifeStance Health Group, Inc.: Amended bylaws to update advance notice provisions for universal proxy rules, conform to DGCL, and make administrative changes (effective 2023-03-06).
  - Change: bylaw amendment
  - Effective: 2023-03-06
  source text: On March 6, 2023, the Board of Directors (the “Board”) of the Company approved Second Amended and Restated Bylaws of the Company (the “Amended Bylaws”), effective immediately, with such amendments including updates to the advance notice provisions to address the adoption by the Securities and Exchange Commission (the “SEC”) of “universal proxy” rules and other updates to conform with the Delaware General Corporation Law (the “DGCL”) regarding notice of adjourned stockholder meetings and stockholder list requirements.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1845257/000095017023006541/0000950170-23-006541-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.